Damages of Cardiovascular System at Mucopolysaccharidosis Type I: Clinical Cases

Damages of Cardiovascular System at Mucopolysaccharidosis Type I: Clinical Cases

Background. Cardiac involvement in patients with mucopolysaccharidosis (MPS) type I, or Hurler syndrome, has various phenotypes.Clinical Case Description. In the first case symptoms were indicative of acute severe heart failure which was confirmed by laboratory and instrumental diagnostic methods. L...

Full description

Bibliographic Details
Main Authors:	Elena S. Vasichkina, Tatyana L. Vershinina, Tatyana S. Kovalchuk, Ekaterina N. Blinova, Elizaveta V. Malkina, Tatyana M. Pervunina
Format:	Article
Language:	English
Published:	"Paediatrician" Publishers LLC 2020-01-01
Series:	Voprosy Sovremennoj Pediatrii
Subjects:	mucopolysaccharidosis children heart failure cardiomyopathies enzyme replacement therapy diagnostics
Online Access:	https://vsp.spr-journal.ru/jour/article/view/2232

Similar Items

CARDIOVASCULAR PATHOLOGY IN CHILDREN WITH TYPE I MUCOPOLYSACCHARIDOSIS
by: N. D. Vashakmadze, et al.
Published: (2014-07-01)

Neonatal heart failure and noncompaction/dilated cardiomyopathy from mucopolysaccharidosis. First description in literature
by: Francesca Miselli, et al.
Published: (2021-03-01)

EFFECTIVENESS OF MODERN METHODS OF TREATING TYPE I MUCOPOLYSACCHARIDOSIS PATIENTS
by: L. S. Namazova-Baranova, et al.
Published: (2014-11-01)

Evaluation of Demographic and Clinical Characteristics of Patients with Mucopolysaccharidosis
by: Pelin Teke Kısa, et al.
Published: (2017-06-01)

Experience of Idursulfase Beta Administration in the Child with Mucopolysaccharidosis Type II: Clinical Case
by: Tatiana K. Kruchina, et al.
Published: (2020-12-01)

Mucopolysaccharidosis type II: Enzyme Replacement Therapy Efficiency
by: Nato D. Vashakmadze, et al.
Published: (2020-02-01)

EFFICACY AND SAFETY OF ENZYME REPLACEMENT THERAPY IN CHILDREN WITH MUCOPOLYSACCHARIDOSIS TYPE I, II, AND VI: A SINGLE-CENTER COHORT STUDY
by: Liliia A. Osipova, et al.
Published: (2018-04-01)

MODERN APPROACHES TO THERAPY FOR CHILDREN WITH MUCOPOLYSACCHARIDOSIS
by: N. V. Buchinskaya, et al.
Published: (2014-05-01)

Clinical case of mucopolysaccharidosis type II (Hunter syndrome)
by: E. V. Savelieva, et al.
Published: (2021-03-01)

Respiratory Dysfunction in Children and Adolescents with Mucopolysaccharidosis Types I, II, IVA, and VI
by: Assel Tulebayeva, et al.
Published: (2020-01-01)

Cardiac features and effects of enzyme replacement therapy in Taiwanese patients with Mucopolysaccharidosis IVA
by: Hsiang-Yu Lin, et al.
Published: (2018-08-01)

Non-Neuropathic Form of Mucopolysaccharidosis Type II: Clinical Cases
by: Nato D. Vashakmadze, et al.
Published: (2021-03-01)

Aortic Root Dilatation in Mucopolysaccharidosis I–VII
by: Meena Bolourchi, et al.
Published: (2016-11-01)

A case report of a patient with mucopolysaccharidosis type II
by: M.R. Rivera Vega, et al.
Published: (2017-04-01)

Visual Dysfunction of Type I and VI Mucopolysaccharidosis Patients Evaluated with Visual Evoked Cortical Potential
by: Bruno Duarte Gomes, et al.
Published: (2012-03-01)

Cardiac manifestations and effects of enzyme replacement therapy for over 10 years in adults with the attenuated form of mucopolysaccharidosis type I
by: Kenta Sugiura, et al.
Published: (2020-12-01)

Bull's eye maculopathy and subfoveal deposition in two mucopolysaccharidosis type I patients on long-term enzyme replacement therapy
by: Heather G. Mack, et al.
Published: (2018-03-01)

Home treatment of type VI mucopolysaccharidosis (Maroteaux‐Lamy syndrome) an alternative at this time of COVID‐19 pandemic: A case in Peru
by: Jenny Lucy Cortez Miranda, et al.
Published: (2020-12-01)

Enzyme replacement therapy for Mucopolysaccharidosis Type I among patients followed within the MPS Brazil Network
by: Alícia Dorneles Dornelles, et al.
Published: (2014-01-01)

Orthopedic Pathology in Children with Mucopolysaccharidosis Type I
by: Nato D. Vashakmadze, et al.
Published: (2016-12-01)

Diagnostic journey and impact of enzyme replacement therapy for mucopolysaccharidosis IVA: a sibling control study
by: Can Ficicioglu, et al.
Published: (2020-11-01)

Role of elosulfase alfa in mucopolysaccharidosis IVA
by: Regier DS, et al.
Published: (2016-06-01)

Recovery of Vision following Enzyme Replacement Therapy in a Patient with Mucopolysaccharidosis Type II, Hunter Syndrome
by: Ryutaro Yamanishi, et al.
Published: (2019-06-01)

Enzyme replacement therapy interruption in mucopolysaccharidosis type IVA patients and its impact in different clinical outcomes
by: Juan Politei, et al.
Published: (2021-03-01)

Open issues in Mucopolysaccharidosis type I-Hurler
by: Rossella Parini, et al.
Published: (2017-06-01)

Mucopolysaccharidosis Type I
by: Francyne Kubaski, et al.
Published: (2020-03-01)

C-type natriuretic peptide restores growth impairment under enzyme replacement in mice with mucopolysaccharidosis VII
by: Yamashita, Takafumi
Published: (2020)

Cardiovascular findings and effects of enzyme replacement therapy in patients with mucopolysaccharidosis type VI
by: Emine Azak, et al.
Published: (2019-10-01)

Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I
by: Roberto Giugliani, et al.
Published: (2017-03-01)

Long-term galsulfase enzyme replacement therapy in Taiwanese mucopolysaccharidosis VI patients: A case series
by: Hsiang-Yu Lin, et al.
Published: (2016-06-01)

Mucopolysaccharidosis Type I: Current Treatments,Limitations and Prospects for Improvement
by: Christiane S. Hampe, et al.
Published: (2021-01-01)

A review of the clinical outcomes in idursulfase-treated and untreated Filipino patients with mucopolysaccharidosis type II: data from the local lysosomal storage disease registry
by: Marie Julianne C. Racoma, et al.
Published: (2021-07-01)

Clinical characteristics and effects of enzyme replacement therapy with elosulfase alfa in Korean patients with mucopolysaccharidosis type IVA
by: Cho, T.-J, et al.
Published: (2022)

Association of somatic burden of disease with age and neuropsychological measures in attenuated mucopolysaccharidosis types I, II and VI
by: Alia Ahmed, et al.
Published: (2016-06-01)

A new strategy of desensitization in mucopolysaccharidosis type II disease treated with idursulfase therapy: A case report and review of the literature
by: Burlina, A.B, et al.
Published: (2022)

Cardiac disease as the presenting feature of mucopolysaccharidosis type IIIA: A case report
by: Erlane Marques Ribeiro, et al.
Published: (2014-01-01)

Individual heat map assessments demonstrate vestronidase alfa treatment response in a highly heterogeneous mucopolysaccharidosis VII study population
by: Christine Haller, et al.
Published: (2019-09-01)

Failure to shorten the diagnostic delay in two ultra-orphan diseases (mucopolysaccharidosis types I and III): potential causes and implications
by: Gé-Ann Kuiper, et al.
Published: (2018-01-01)

Diagnostic Difficulties of Mucopolysaccharidosis Type I Mild Forms: Clinical Cases
by: Nato D. Vashakmadze, et al.
Published: (2020-06-01)

Enzyme replacement therapy: efficacy and limitations
by: Daniela Concolino, et al.
Published: (2018-11-01)

Cannot write session to /tmp/vufind_sessions/sess_4jq9ed6jchoffl49gnjqsrj18v